ClinicalTrials.gg
RecruitingNCT07354022Updated Jun 2, 2026

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

A Phase 3 interventional study of HRS-8080 Tablet ; Dalpiciclib Isethionate and Fulvestrant injection ;Dalpiciclib Isethionate in Locally Advanced or Metastatic Breast Cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
912
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing HRS-8080 in Breast Neoplasms — 8 open to participants now, 8 under way, 3 of them phase 3. HRS-8080 · Breast Neoplasms.

Planned enrollment
2nd of 11
912 · median 180
Started
2026
with 4 others
Phase 3
3 of 11
3 open now
Registered
8th of 11
by date
Lead sponsor
11 of 11
Shandong Suncadia Medicine Co., Ltd.

Among the 11 studies testing HRS-8080 in Breast Neoplasms, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2026, is one of 3 in phase 3, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 11 studies testing HRS-8080 in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About HRS-8080

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing HRS-8080 in Breast Neoplasms, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.

03

Conditions studied

  • Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 - 75 years old;
  2. performance status (ECOG-PS) of 0 to 1;
  3. Patients with confirmed locally advanced or breast cancer;
  4. Patients with prior endocrine resistance following curative-intent surgery;
  5. Menstrual status: , perimenopausal, or premenopausal;
  6. Presence of evaluable lesions;
  7. Organ function must meet required criteria.

Exclusion criteria

Exclusion Criteria:

  1. Patients with rapidly progressing disease, as judged by the investigator to be unsuitable for endocrine therapy;
  2. Patients who have previously received fulvestrant or other novel SERMs (excluding tamoxifen and toremifene);
  3. Patients with uncontrolled , carcinomatous meningitis, or spinal cord compression;
  4. Patients with a history of cardiovascular disease;
  5. Participants who have not recovered from adverse effects caused by prior therapies;
  6. Participants with a history of another within the past 5 years or currently having another malignancy;
  7. Known to HRS-8080, fulvestrant, dalpiciclib, or any of their components, etc.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
912 participants (estimated)

Study arms

  • Experimental
    HRS-8080 combined with Dalpiciclib

    Drug: HRS-8080 Tablet ; Dalpiciclib Isethionate

  • Active comparator
    Fulvestrant combined with Dalpiciclib

    Drug: Fulvestrant injection ;Dalpiciclib Isethionate

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator assessed Progression free survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), or death from any cause during the study.

    Time frame: Up to 5 years.

Secondary outcomes

  1. Progression free survival (PFS) evaluated by the blinded independent central review (BICR)

    Time frame: Up to 5 years

  2. Overall response rate (ORR)

    Time frame: Up to 5 years

  3. Clinical benefit rate (CBR)

    Time frame: Up to 5 years

  4. Duration of response (DOR)

    Time frame: Up to 5 years

  5. Overall survival (OS)

    Time frame: Up to 8 years

  6. The incidence and severity of adverse events (AEs)

    Time frame: Up to 5 years

  7. The incidence and severity of serious adverse events (SAEs)

    Time frame: Up to 5 years

  8. Number of participants with vital sign abnormalities over the course of the study. Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure, and temperature

    Time frame: Up to 5 years

  9. Number of participants with clinical laboratory test abnormalities for haematology and biochemistry parameters over the course of the study

    Time frame: Up to 5 years

  10. Heart rate (beats per minute) measured by 12-lead electrocardiography.

    Time frame: Up to 5 years

  11. QT interval (ms) measured by 12-lead electrocardiography.

    Eastern Cooperative Oncology Group (ECOG) performance status. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

    Time frame: Up to 5 years

  12. Plasma concentrations of HRS-8080 and dalpiciclib isethionate

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
  • Chinese PLA General Hospital Fifth Medical Center
    Beijing, Beijing Municipality 100000, China
    Recruiting
    • Zefei Jiang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 31 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 21, 2026
StartActual
May 5, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2031
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07354022
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
May 5, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2031 (estimated)
Last update
Jun 2, 2026

Study contacts

Zhan Zhang
Contact
Zhan.zhang@hengrui.com
+86 17721286165

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-8080 · Dalpiciclib isethionate

Start the discussion